Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis. (PubMed, Rheumatol Ther) - Oct 16, 2026 - P | "At 6 and 12 months, there were no significant differences in achieving or maintaining CDAI remission and LDA for tofacitinib versus TNFi, abatacept, and IL-6i among the overall and TNFi-experienced RA population in US clinical practice. Subgroup analyses suggest some potential HTE; however, interpretation is limited by the small number of outcome events."
Journal • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Oncology • Rheumatoid Arthritis • Rheumatology • Sjogren's Syndrome • IL6
|
|
Arne Yndestad; Chandrasekar Gopalakrishnan; Geneviève Gauthier; Griffith Bell; Jinoos Yazdany; Katherine P Liao; Milena A Gianfrancesco; Suraj Sarvode Mothi
|